fda statement bpc-157 not approved safety warning In a major policy shift, the U.S. Food and Drug Administration is reconsidering restrictions on several controversial peptides, including trending compounds like and Melanotan II. The move comes as demand for “ fda warning bpc-157 compounded peptide
Description
Put me down for interested and curious but skeptical
"BREAKTHROUGH MEDICAL WEIGHT LOSS SOLUTIONS," one read
150 Other observational studies have reported declining DHEA-S levels were associated with increased risk of type 2 diabetes in men
For example, the recently published article by Diaz-Villares et al 2023 demonstrates a significantly increase in the retention time of a senolytic peptide for the treatment of osteoarthritis after intra-articular injection, when the peptide was loaded into biodegradable nanosystems, in relation to the free peptide [3]
